20
Participants
Start Date
October 17, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
April 30, 2027
immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Ruijin Hospital
OTHER